comprehensive -WSS

comprehensive

author：focus 2025-09-27 14:34:39 - browse：82

Adobe

The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday.

The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees. And it opens the door for other Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses — even though many independent experts believe the quality rating system is flawed and doesn’t appropriately gauge quality of care for older adults and people with disabilities.

The Centers for Medicare and Medicaid Services, the federal agency that oversees all Medicare programs, said it does not comment on litigation. In an interview, SCAN CEO Sachin Jain told STAT that if the company had not gotten its expected bonus money, it would have had to shave benefits and reduce what it pays hospitals and doctors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： WHO recommends second malaria vaccine

entertainment

WSS

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Nobel honors Karikó and Weissman's enduring partnership

Will an HIV vaccine ever be a reality?

Creating egg and sperm cells from stem cells raises ethical issues

Stop the failed accountable care organization experiment

Some top drug companies are starting to take action on climate

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

explore

Wildfire smoke exposes gaps in outdoor worker protections

Creating egg and sperm cells from stem cells raises ethical issues

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Creating egg and sperm cells from stem cells raises ethical issues

The cancer drug shortage isn’t new — and neither are the solutions

SCOTUS questions limit to govt efforts to fight misinformation

How one medical school became remarkably diverse

RSV injection headlines need to be accurate for good uptake

Medical leaders decry Supreme Court decision on affirmative action

Colonoscopy prep: Liquid

Wikipedia

The biotech scorecard for Q4: 16 stock

Asbestos, a deadly carcinogen, banned by EPA

IVG is promising — but it won’t replace IVF quite yet

U.K. researchers warn about biases in medical devices, algorithms

Creating egg and sperm cells from stem cells raises ethical issues

Virtual Event: March of the Biosimilars

entertainment

entertainment

explore

hotspot